Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Menarini Group

Tracked across 3 events · 49 articles · First seen May 25, 2026 · Last active Jul 21, 2026

Sentiment
52
Attention
7
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Tech
Impact: Menarini Group announced positive Phase 3 SENTRY trial data for selinexor plus ruxolitinib in myelofibrosis, which could lead to a new treatment option and enhance its market position in oncology.
Jun 14, 2026 · 8 articles
7 70
Tech
Impact: Menarini Group, along with its subsidiary AnBogen Therapeutics, Inc., presented new data related to elacestrant and tagraxofusp at the ASCO Annual Meeting, highlighting its commitment to oncology treatments and potentially boosting its product portfolio.
May 25, 2026 · 33 articles
2 10
Business
Impact: As parent company of Menarini Asia-Pacific, the Menarini Group benefits from the partnership through expanded market presence in Asia-Pacific.
Jul 21, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Menarini Group live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.